FilingSEC EDGAR8-K
Rezolute Provides Update on ersodetug Clinical Progress and Corporate Strategy
· SEC accepted
StageClinical and Strategy Update
Filing content
The company shared results from the ersodetug Phase 3 study and plans for BLA submission, noting it has sufficient cash runway through Q1 2028.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…